Linesol (Linezolid)

Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing the formation of the initiation complex required for translation. This blocks bacterial growth, producing a bacteriostatic effect against susceptible Gram‑positive organisms.

The prescribed dose of Linesol is determined by the treating physician based on the specific infection, patient weight, renal and hepatic function, and local prescribing guidelines. Dosage regimens are not disclosed here.

Safety data for linezolid in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Linesol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Linesol (linezolid) offers oral and intravenous options, good tissue penetration, and activity against MRSA strains resistant to many other agents. Compared with vancomycin, it does not require therapeutic drug monitoring and has a different side‑effect profile, though both are considered first‑line for serious MRSA infections.

Linesol should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Maintaining the cold‑chain ensures stability and potency of the injectable solution.

Linesol is supplied as an injectable solution for intravenous infusion. It is administered by a healthcare professional under aseptic conditions, typically diluted in compatible IV fluids and infused over a prescribed period according to the prescriber’s instructions.

Serious risks include thrombocytopenia, anemia, peripheral neuropathy, serotonin syndrome when combined with serotonergic drugs, severe hepatic injury, and lactic acidosis. Patients should be monitored regularly for hematologic and neurologic changes during therapy.

Linesol is contraindicated in patients with known hypersensitivity to linezolid or any component of the formulation. Caution is advised for individuals taking MAO inhibitors, serotonergic agents, or those with pre‑existing severe bone‑marrow suppression.